Effect of 3-Month Repeated Administration of Miglitol on Vascular Endothelial Function in Patients With Diabetes Mellitus and Coronary Artery Disease

详细信息    查看全文

• 作者：Takuo  ; Emoto MD^a ; Takahiro  ; Sawada MD^a ;   ; ^{taktak319@yahoo.co.jp} ; Megumi  ; Hashimoto MT^b ; Hiroko  ; Kageyama MT^b ; Daisuke  ; Terashita MD^a ; Taiji  ; Mizoguchi MD^a ; Takao  ; Mizuguchi MD^a ; Yoshiki  ; Motodi MD^a ; Masamichi  ; Iwasaki MD^a ; Kazuki  ; Taira MD^a ; Hiroshi  ; Okamoto MD^a ; Yosuke  ; Matsuo MD^a ; Sushi-ku  ; Kim MD^a ; Akira  ; Takarada MD^a ; Mitsuhiro  ; Yokoyama MD^a
• 刊名：The American Journal of Cardiology
• 出版年：2012
• 出版时间：1 January 2012
• 年：2012
• 卷：109
• 期：1
• 页码：42-46
• 全文大小：479 K

文摘

Repeated postprandial hyperglycemia may play an important role in the development of atherosclerosis by suppressing vascular endothelial function. Although miglitol suppresses the elevation of blood glucose levels shortly after a meal more than other ¦Á-glucosidase inhibitors, the effect of 3-month repeated administration of miglitol on endothelial dysfunction is unknown. Fifty patients with type 2 diabetes and coronary artery disease were enrolled in the present study. The patients were randomly divided into 2 groups, the first treated with miglitol and the second with voglibose for 3 months. Blood chemistry (lipid and blood glucose profiles, glycosylated hemoglobin, 1,5-anhydroglucitol, serum insulin levels, and C-reactive protein) and flow-mediated dilatation were measured at the beginning and end of the trial period. Patient characteristics and blood chemistry of the 2 groups were similar at the beginning of the trial. At the end of the trial, glycosylated hemoglobin decreased in the 2 groups, but the improvements in 1,5-anhydroglucitol in the miglitol group were significantly higher than in the voglibose group. Insulin resistance index, C-reactive protein, and percentage flow-mediated dilatation were also improved in the miglitol group but not in the voglibose group. In conclusion, 3-month repeated administration of miglitol improved vascular endothelial dysfunction by strongly suppressing postprandial hyperglycemia. Miglitol may have antiatherogenic effects in patients with type 2 diabetes and coronary artery disease.